Abstract:

Malignant mesothelioma (MM) arises from the mesothelial surfaces of the pleural cavity, peritoneal cavity, tunica vaginalis, or pericardium. MM is a rare and insidious neoplasm with a poor prognosis. Malignant pleural mesothelioma (MPM) is the most common type and typically arises from the mesothelial surfaces of the pleural cavity. MPM can be difficult to treat because most patients have advanced disease at presentation. The average survival of patients is between 6 and 18 months. However, carefully selected patients with localized disease who receive aggressive multimodality therapy have relatively prolonged survival. In this review, we aimed to evaluate the results of surgery, radiotherapy, chemotherapy, targeted therapy and immunotherapy studies to improve survival in MPM.

Keywords: